Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071840 | 1.00 | NCF1 (0.55) | NCF1BACE1CYP1A2CYP2C19HTT | |
| SCHEMBL26654324 | 0.88 | BACE1 (0.50) | NCF1BACE1CYP1A2CYP2C19HTT | |
| SCHEMBL1544058 | 0.86 | BACE1 (0.55) | NCF1BACE1CYP1A2CYP2C19HTT | |
| SCHEMBL18572141 | 0.82 | BACE1 (0.48) | NCF1BACE1CYP1A2CYP2C19HTT | |
| SCHEMBL26654128 | 0.82 | BACE1 (0.57) | NCF1BACE1CYP1A2CYP2C19HTT | |
| SCHEMBL25775423 | 0.81 | BACE1 (0.47) | NCF1BACE1CYP1A2CYP2C19HTT | |
| SCHEMBL18572135 | 0.81 | BACE1 (0.47) | NCF1BACE1CYP1A2CYP2C19HTT | |
| SCHEMBL18317020 | 0.78 | DYRK1A (0.54) | BACE1CYP1A2CYP2C19HTTEGFR | |
| SCHEMBL13908259 | 0.77 | CYP1A2 (0.59) | NCF1BACE1CYP1A2HTTMEN1 | |
| SCHEMBL18572138 | 0.76 | BACE1 (0.46) | BACE1CYP1A2CYP2C19HTTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2024-04-09 | — | — | US | disclosed |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| US-11459330-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | LUPIN LIMITED (IN) | 2022-10-04 | — | — | US | disclosed |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | LUPIN LIMITED (IN) | 2022-08-25 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | NCF1 2096/4885BACE1 1835/4885CYP1A2 3501/4885 |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | NCF1 1596/4885BACE1 2184/4885CYP1A2 2522/4885 |
| US-11459330-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NCF1 3660/4885BACE1 1210/4885CYP1A2 1181/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | NCF1 1797/4885BACE1 2198/4885CYP1A2 2244/4885 |
| US-20220267339-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | NCF1 3660/4885BACE1 1210/4885CYP1A2 1181/4885 |
| US-11952380-B2 | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NCF1 3660/4885BACE1 1210/4885CYP1A2 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.